Ovarian cancer vaccine - MabVax/MSKCC

Drug Profile

Ovarian cancer vaccine - MabVax/MSKCC

Alternative Names: MV-Ovar; NSC-748933; Polyvalent vaccine-KLH conjugate - MabVax

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Gynecologic Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 10 Jun 2015 Phase-II development in Ovarian cancer is ongoing in the US
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
  • 28 May 2013 Memorial Sloan-Kettering Cancer Center completes enrolment in its phase II trial for Ovarian cancer in USA (NCT00857545)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top